ReNerve

ASX Announcement

13 November 2025

NervAlign® approved for use in US Department of Defense (DoD) & Veterans Affairs (VA) healthcare systems

- **NervAlign® Nerve Cuff approved for use in DoD and VA hospitals**
- **Initial order and reorder received from the DoD and VA network**
- **Further validation of the quality of NervAlign® in peripheral nerve repair**

ReNerve Limited (ASX, "**ReNerve**" or "the **Company**"), a leading Australian medical device innovator focused on solutions for peripheral nerve injury (PNI), is pleased to announce that its NervAlign® Nerve Cuff has been approved for use across the US Department of Defense (DoD) and Veterans Affairs (VA) healthcare systems, representing a significant endorsement of ReNerve's NervAlign® nerve cuff technology.

The approval allows the NervAlign® Nerve Cuff to be used across the DoD's 51 military hospitals and 424 clinics, as well as VA's 170 medical centres and over 1,193 outpatient facilities, providing ready access to this innovative technology to those of the approximately 9.5 million patients across both healthcare systems who may benefit from its use.

Under this approval, ReNerve has received both an initial purchase order and a subsequent repeat order from federal medical facilities, demonstrating early confidence in the NervAlign® system. These orders will enable immediate deployment of the technology to select facilities within both the DoD and VA networks, with a broader rollout planned for the coming months.

"This approval represents major progress in our mission to provide superior nerve repair solutions to those who need them most," said Dr Julian Chick, CEO of ReNerve. "Military service members and veterans often face complex peripheral nerve injuries, and we are honoured and proud that the NervAlign® Nerve Cuff will now be available to support their recovery and rehabilitation."

The NervAlign® Nerve Cuff represents a significant advancement in peripheral nerve repair technology, offering clinicians a precise and effective solution for supporting nerve regeneration and recovery following traumatic injuries, surgical procedures, and other conditions affecting peripheral nerves.

About the Federal Healthcare Networks

The Military Health System operates through the Defence Health Agency, managing healthcare delivery across 51 hospitals and 424 clinics serving military personnel, their families, and retirees. The Veterans Health Administration operates the largest integrated healthcare system in the United States, with 170 medical centres and 1,193 outpatient sites of care, providing comprehensive medical services to veterans nationwide.

Visit renerve.com.au for more details and updates on ReNerve products and clinical news.

- ENDS -

This announcement has been approved for release by the Company's Board of Directors.

For further information and enquiries, please contact:

Dr Julian Chick
CEO & Managing Director
ReNerve Ltd
+61 (03) 9482 3940
info@renerve.com.au

Matthew Wright
Investor & Media Relations
NWR Communications
+61 (0) 451 896 420
matt@nwrcommunications.com.au

About ReNerve Limited (ASX:RNV)

ReNerve Limited (ASX:RNV) is transforming nerve repair and improving lives through breakthrough medical technology. Founded by a neurosurgeon and medtech researchers, ReNerve is a rapidly growing medical device company that has revolutionised peripheral nerve surgery with its innovative, ready-to-use solutions for peripheral nerve injuries (PNI). Our scientifically backed products are delivering measurably better outcomes for patients worldwide.

Proven Clinical Success

ReNerve's first flagship product, the FDA-cleared **NervAlign® Nerve Cuff**, is already making a dramatic difference in surgical outcomes across the United States. A recently announced clinical study has demonstrated remarkable results, showing that patients treated with the NervAlign® Nerve Cuff experienced post-surgical pain scores dropping from 7.1 to just 0.4, compared to from 7.1 to 3.3 without the device being used – a statistically significant improvement that's changing lives.

Comprehensive Product Portfolio

ReNerve is advancing a complete suite of nerve repair solutions:

- **NervAlign® Nerve Cuff** – Our bioabsorbable protective wrap, naturally absorbed within six months of surgery.
- **Deep Dermal tissue product --** A unique deep dermal product used in the repair of reconstructive and cosmetic surgical cases.
- **Amniotic tissue product ranges --** Three amniotic tissue product ranges used to aid the healing of wounds.
- **NervAlign® Nerve Conduit Range –** Next-generation nerve conduit leveraging advantages of eCOO technology in a material designed to facilitate nerve growth over short gaps between nerve ends.
- **NervAlign® Nerve Guide Matrix** – a customised and ready-to-use alternative to existing nerve grafts, for treatment of longer nerve gaps and more severe nerve injuries. It will eliminate the need for patients to undergo additional sural nerve harvesting.

- **NervAlign® Bionic Nerve** – Next-generation combination technology for the most challenging nerve repairs.

Market Leadership and Growth

With demonstrated market traction since the Company's 2022 product launch, ReNerve achieved 53% revenue growth in FY25, reaching $271k in sales. Our high-margin, scalable products are positioning us as the go-to solution for surgeons seeking superior patient outcomes in the rapidly expanding global nerve repair market, valued at US$1.6 billion in 2024 and is projected to reach $6.2 billion by 2031.[1]

Vision and Values

We're not just developing medical devices – we're engineering hope. By creating the ideal healing environment for nerve repair and regeneration, ReNerve bridges critical gaps in healthcare while empowering the human body's natural healing process. Our cleaner, safer, and more effective solutions represent the future of peripheral nerve surgery.

[1] Global Nerve Repair Biomaterials Market Research Report (2020 – 2031)